Concepedia

Author

Sitaram Ghogale

Tata Memorial Hospital

Also Known As

Prashant Tembhare, S Ghogale, S. Ghogale, Sitaram G Ghogale, Sitaram G. Ghogale, Sitaram Ghogale, Sitaram Gundu Ghogale

62

Publications

537

Citations

13

H-Index

0

Concepts

All Affiliations

Tata Memorial HospitalAdvanced Centre for Treatment, Research and Education in CancerHomi Bhabha National Institute
SG

About

Sitaram Ghogale is an author at Tata Memorial Hospital.

Sitaram Ghogale

×

16

Publications

449

Citations

13

H-Index

YearCitations

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10<sup>6</sup>and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant Tembhare, Papagudi Ganesan Subramanian, Sitaram Ghogale,

Cytometry Part B Clinical Cytometry

2019

74

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Prashant Tembhare, Sitaram Ghogale, Nisha Ghatwai,

Cytometry Part B Clinical Cytometry

2016

63

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Prashant Tembhare, Harshini Sriram, Twinkle Khanka,

Journal for ImmunoTherapy of Cancer

2020

41

A novel and easy <scp>F</scp>xCycle<scp>™</scp> violet based flow cytometric method for simultaneous assessment of <scp>DNA</scp> ploidy and six‐color immunophenotyping

Prashant Tembhare, Yajamanam Badrinath, Sitaram Ghogale,

Cytometry Part A

2015

39

Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients

Prashant Tembhare, Gaurav Narula, Twinkle Khanka,

Frontiers in Oncology

2020

32

Improved protocol for plasma microRNA extraction and comparison of commercial kits

Harshini Sriram, Nilesh Deshpande, Prashant Tembhare,

Biochemia Medica

2021

27

Eleven‐marker 10‐color flow cytometric assessment of measurable residual disease for T‐cell acute lymphoblastic leukemia using an approach of exclusion

Prashant Tembhare, Gaurav Chatterjee, Twinkle Khanka,

Cytometry Part B Clinical Cytometry

2020

25

Utility of <scp>CD36</scp> as a novel addition to the immunophenotypic signature of <scp>RAM</scp>‐phenotype acute myeloid leukemia and study of its clinicopathological characteristics

Devasis Panda, Gaurav Chatterjee, Rohan Sardana,

Cytometry Part B Clinical Cytometry

2020

22

CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—Immunophenotypic challenges in diagnosis and monitoring: A study of three cases

Kiran Ghodke, Asma Bibi, Nikhil Rabade,

Cytometry Part B Clinical Cytometry

2016

21

CD304/neuropilin‐1 is a very useful and dependable marker for the measurable residual disease assessment of B‐cell precursor acute lymphoblastic leukemia

Pratyusha Gudapati, Twinkle Khanka, Gaurav Chatterjee,

Cytometry Part B Clinical Cytometry

2020

21

Page 1